Amgevita (Adalimumab)
adalimumab 20 mg/0.4 mL injection, 0.4 mL syringe · INJECTION · PBS code 15005R
STREAMLINEDWhat it costs
AU$272.84 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2025-09-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe chronic plaque psoriasis
Subsequent continuing treatment, Whole body
Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND
Patient must have demonstrated an adequate response to treatment with this drug; AND
Patient must have been assessed for response to treatment after at least 12 weeks treatment with the preceding supply of this biological medicine; AND
Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND
Must be treated by a dermatologist; AND
Patient must have been under 18 years of age at the time of initial treatment with this drug.
An adequate response to treatment is defined as:
A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the baseline value for this treatment cycle.
The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.
The assessment of response to treatment must be documented in the patient's medical records.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe chronic plaque psoriasis
Subsequent continuing treatment, Face, hand, foot
Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND
Patient must have demonstrated an adequate response to treatment with this drug; AND
Patient must have been assessed for response to treatment after at least 12 weeks treatment with the preceding supply of this biological medicine; AND
Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND
Must be treated by a dermatologist; AND
Patient must have been under 18 years of age at the time of initial treatment with this drug.
An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing:
(i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the baseline values; or
(ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the baseline value for this treatment cycle.
The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.
The assessment of response to treatment must be documented in the patient's medical records.
Sponsor: Arrotex Pharmaceuticals Pty Ltd ABN 30 605 552 234
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.